View Older Stories View More Recent Stories
-
Roth Capital Upgrades Maxwell Technologies (MXWL) to Buy
-
Celldex (CLDX) Upcoming Clinical Data, Study Expansions, Pipeline Keep Roth Positive; 'Focus List' Rating Affirmed
-
Roth Comments on Palatin's (PTN) BMT Agreement with European Partner; Reaffirms 'Buy' Rating
-
Viggle, Inc. (VGGL) Closes 4.38M Common Offering for Gross Proceeds of $35M
-
Roth Positive on Cytokinetics (CYTK) Following BENEFIT-ALS Update; Several Points Go in Tirasemtiv's Favor
-
Roth Affirms Ligand (LGND) at Buy; FDA Grants Promacta/Revolade Priority Review
-
Roth Capital Upgrades Trinity Biotech (TRIB) to Buy
-
New BENEFIT-ALS Data from Cytokinetics (CYTK) is 'Exciting'; Investors Should Regain Confidence - Roth
-
Roth Capital Downgrades Ultra Clean (UCTT) to Neutral
-
DoD Supporting Galena's (GALE) NeuVax Provides Important Third-Party Scientific Validation - Roth
-
Viggle, Inc. (VGGL) NASDAQ Uplisting/IPO Opens Lower
-
Roth Slashes PT on Cytokinetics (CYTK) to $13; ALS Call Missed, but Omecamtiv Provides Buffer
-
Viggle, Inc. (VGGL) Prices Larger 4.38M Common Offering at $8 Apiece
-
Zerenex Costs Savings, Differentiation Highlighted; PDUFA Date Still in Focus (KERX) - Roth Capital
-
Roth 'Encouraged' to See Bavituximab Moving Forward; Affirms Peregrine Pharma (PPHM) at 'Buy'
-
Roth Capital Pounds Table on Cytokinetics (CYTK) into AAN BENEFIT-ALS Presentation
-
Roth Capital Starts GSV Capital (GSVC) at Buy
-
Notable Analyst Rating Changes 04/21: (MS) (AWI) (HNI) Upgraded; (WLT) (MGI) (YUM) Downgraded
-
Roth Capital Starts Applied Genetic Tech (AGTC) at Buy; Catalysts in 2015 Add Appeal
-
Roth Affirms Clean Diesel (CDTI) at 'Buy'; Sees L-T, Catalyst-Focused Strategy Playing Out
-
xG Technology (XGTI) Prices 5.27M Common Offering at $1.90/Share
-
Low European Exposure Boosts JA Solar (JASO) in Q1 - Analyst
-
Roth Affirms Bullish Position on Retrophin (RTRX) Following Financial, Pipeline Updates
-
Roth Capital Starts AcelRx Pharmaceuticals (ACRX) at Buy
-
Roth Capital Upgrades PriceSmart (PSMT) to Buy
-
Trina Solar (TSL) Follows Suit in Q1 as Europe Lowers Floor Price; Roth Maintains at 'Buy'
-
Mixed Prelim. Q1 Numbers from Yingli Green Energy (YGE) Keep Roth at 'Neutral'
-
NTN Buzztime (NTN) Prices 11.1M Offering at 55c/Share
-
Roth Capital Starts Flamel Technologies (FLML) at Buy
-
Roth Boosts PT on Sunesis Pharma (SNSS) to $15; Focus Remains on Vosaroxin
-
PlacementTracker Publishes First Quarter 2014 PIPE Market League Tables
-
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
-
Pharmacyclics' (PCYC) IMBRUVICA Should Get Full Approval Before End of 2014; Roth Keeps at 'Buy'
-
Streetinsider.com's Hot Lunchtime Reads 04/07: (KR) (MSFT) (SRPT) (MDVN)
-
Pre-Clinical Data for MEI Pharma's (MEIP) Pracinostat Will Set Development Tone - Roth Capital
-
American Apparel (APP) Price Target Reduced to $0.75 at Roth
-
Roth Affirms Hydrogenics (HYGS) at 'Bur'; Customer-Driven Hiccup Doesn't Affect Overall Thesis
-
Ocean Power Technologies (OPTT) Prices 3.8M Offering at $3.10/sh
-
Ocean Power Technologies Prices Underwritten Public Offering of Common Stock
-
Roth Capital Starts Energy Fuels (UUUU) at Buy
-
Roth Capital Starts Uranium Resources (URRE) at Buy
-
Ocean Power Technologies, Inc. (OPTT) Plans Common Stock Offering
-
Ocean Power Technologies Announces Proposed Public Offering of Common Stock
-
SolarCity (SCTY) ABS Offerings are Evolutionary Step Toward Lower-Cost Financing - Roth
-
AGTC Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Catyalyst Pharma (CPRX) Prices 11.33M Common Offering at $2.21/Share
-
Endocyte (ECYT) Closes 5.18M Offering; Sees Net Proceeds of $101.8M
-
Endocyte, Inc. Closes Public Offering of Common Stock
-
Roth Affirms Keryx (KERX) at 'Buy'; ESRD Overhang Removed
-
Roth Lifts PT on Stemline (STML) to $62; Sees 'Pivotal' Year in 2014

